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Background: Non-randomized studies have investigated multi-agent gemcitabine-
based neo-adjuvant therapies (GEM-NAT) in borderline resectable pancreatic
ductal adenocarcinoma (BR-PDAC). Treatment sequencing and specific elements
of neoadjuvant treatment are still under investigation. The present meta-analysis aims to
assess the effectiveness of GEM-NAT on overall survival (OS) in BR-PDAC.
Patients and Methods: A meta-analysis of individual participant data (IPD) on GEM-
NAT for BR-PDAC were performed. The primary outcome was OS after treatment with
GEM-based chemotherapy. In the Individual Patient Data analysis data were reappraised
and confirmed as BR-PDAC on provided radiological data.
Results: Six studies investigating GEM-NAT were included in the IPD metanalysis.
The IPD metanalysis was conducted on 271 patients who received GEM-NAT.
Pooled median patient-level OS was 22.2 months (95%CI 19.1–25.2). R0 rates
ranged between 81 and 95% (I2 = 0%, p = 0.64), respectively. Median OS was
27.8 months (95%CI 23.9–31.6) in the patients who received NAT-GEM followed
by resection compared to 15.4 months (95%CI 12.3–18.4) for NAT-GEM without
resection and 13.0 months (95%CI 7.4–18.5) in the group of patients who received
upfront surgery (p < 0.0001). R0 rates ranged between 81 and 95% (I2 = 0%,
p = 0.64), respectively. Overall survival in the R0 group was 29.3 months (95%
CI 24.3–34.2) vs. 16.2 months (95% CI 7·9–24.5) in the R1 group (p = 0·001).
Giovinazzo et al. Neoadjuvant in Borderline Resectable Pancreatic Cancer
Conclusions: The present study is the first meta-analysis combining IPD from a
number of international centers with BR-PDAC in a cohort that underwent multi-agent
gemcitabine neoadjuvant therapy (GEM-NAT) before surgery. GEM-NAT followed by
surgical resection improve survival and R0 resection in BR-PDAC. Also, GEM-NAT may
result in a good palliative option in non-resected patients because of progressive disease
after neoadjuvant treatment. Results from randomized controlled trials (RCTs) are awaited
to validate these findings.
Keywords: gemcitabine, gemcitabine-based neoadjuvant, neoadjuvant treatment of pancreatic cancer, Pancreatic
ductal adenocancinoma, Borderline resectable pancreaic adenocarcinoma
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a not uncommon
lethal malignancy, with a 5-year survival of 8% for all the stages.
Patients undergoing resection have 20% survival rate at 5-years
which may be as high as 32% in case of complete resection
and 40% in the subgroup with node-negative disease. Only a
minority of patients, however, are eligible for surgery at the time
of diagnosis, due to metastatic or locally advanced disease (1, 2).
A borderline resectable (BR)-PDAC is a tumor with a
variable degree of vascular contact or involvement that may
not permit a complete resection without vascular resection
and/or reconstruction, making resection challenging, although
technically possible. Various definitions of BR-PDAC have been
proposed but the literature supports that this group of patients
does benefit from surgical resection if a complete resection
(R0) can be reached (3, 4). In addition, recent studies have
suggested that the use of a multimodal neoadjuvant treatment
approach may better select the patient that will benefit from
surgery by increasing the R0 resection rate and improving overall
survival (5–7). Previous studies have focused on the benefit of
neoadjuvant treatment compared to upfront surgery in PDAC,
but there is paucity of evidence on long term outcomes in
BR-PDAC (7).
To date no standard neoadjuvant protocol has been agreed in
BR-PDAC (8–10). Palliative gemcitabine has been a standard of
care in locally advanced or metastatic PDAC for many years and
is used alone or in multi-agent combinations, and in association
with radiotherapy (6). The type of treatment choice is influenced
by individual patient features and status and based on data
available from metastatic PDAC.
The present meta-analysis of individual participant data (IPD)
aimed to assess the impact of the use of neoadjuvant therapies
with Gemcitabine based protocols in patients with borderline
resectable PDAC. The primary outcome of the meta-analysis
was overall survival (OS) in patients who received GEM-NAT
followed by resection.
METHODS
Search Strategy
The systematic review and meta-analysis were conducted in
accordance to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.
A computerized search of PubMed, Embase, Ovid Medline,
and Cochrane Library was carried out. Articles published from
time of inception to February 2020 were included. An advanced
search was performed with the following search mesh terms:
“pancreatic neoplasm and neoadjuvant therapy.” Reference lists
of all obtained and relevant articles were screened manually
and cross-referenced to identify any additional studies. The site
clinicaltrials.gov was interrogated for any ongoing or concluded
trial on the topic with available results.
Outcomes of Interest
The primary outcome was median overall survival (OS) in
patients with BR-PDAC treated with Gemcitabine-based neo-
adjuvant treatments (GEM-NAT) with or without surgical
resection. Secondary outcomes were: complete resection (R0) and
resection rate. In the IPD analysis all stages were re-assessed and
confirmed as BR-PDAC according to NCCN guidelines based on
provided radiological data.
Inclusion Criteria
Studies that reported results on patients diagnosed with BR-
PDAC with the outcome of interest were included in the review.
Studies including both patients with BR-PDAC and with locally
advanced PDAC were only included when the primary outcome
was available for the separate cohort of BR-PDAC. Only data
from the centers who provided anonymized individual patient
data with results on GEM-NAT were included in the IPD
meta-analysis. Articles focused on pancreatic neuroendocrine
neoplasia or other histology were excluded. When two or more
articles were reported from the same institution and/or author,
the one of higher quality or the most recent publication was
included in the analysis.
Abstracts, letters, comments, editorials and expert
opinions, unpublished articles and abstracts, reviews
without original data, case reports were excluded from
the meta-analysis.
Two reviewers (FS and HA) independently screened the
titles and abstracts of all retrieved articles. The full texts of
articles with the potential to fulfill the inclusion criteria were
obtained and checked for eligibility. The following information
was extracted from each article: first author, year of publication,
study design, study population characteristics, number of
subjects treated, type of neo-adjuvant treatment, dropout
rate, procedure-related mortality and morbidity, median and
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FIGURE 1 | PRISMA 2009 flow diagram.
disease-free survival complete oncological resection (R0), and
resection rate.
After selecting eligible articles for meta-analysis, contact
details of authors were gathered from recent articles or
the internet and authors were asked to collaborate with
us. A second request was sent to non-responders 4 weeks
later. Authors who agreed to collaborate were requested
to provide anonymous IPD for clinico-pathological and
radiological characteristics, treatment, postoperative, and long
term outcomes.
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Data Analysis
The meta-analysis was performed using R software suite (v3.4.0,
https://www.R-project.org), and Kaplan Meier curves were
calculated with SPSS (v24, Chicago, IL, USA). Pooled effect
was calculated using either the fixed effects or the random
effects model. Time-to-event methods were used for the median
survival. Hazard Ratio (HR) was derived from ln(HR) and
Standard Error (SE). Studies not reporting p-value for survival
analysis were excluded (11). Statistical heterogeneity between
trials was evaluated by χ2 and I2, with significance being set
at p ≤ 0.10 (12). In the absence of statistically significant
heterogeneity, the fixed-effect method was used to combine
the results. When heterogeneity was confirmed (p ≤ 0.10), the
random-effect method was used. Potential publication bias was
investigated by funnel plot, Egger’s test, was used to assess
funnel plot asymmetry (13) and Makaskill’s test was used to
quantify the bias (14). P < 0.050 (two-tailed) was considered to
indicate statistical significance. The methodological quality of the
individual studies was assessed with the Critical Appraisal Skill
Program (CASP) tool (15).
RESULTS
Literature Search
The number of studies screened, assessed, and excluded is
reported in the PRISMA flow diagram (Figure 1). Eighteen full
text articles were assessed for eligibility and six studies provided
data at an IPD (Table 1) (7, 16–20).
Individual Patient Data Meta-Analysis
The IPD metanalysis was conducted on the data provided on
271 patients who received GEM-NAT. The included studies
showed evidence of an asymmetrical distribution in overall
survival (Test for funnel plot asymmetry: t = 1.4439, df =
4, p = 0.2223) (Figure 2A), resection rate (Test for funnel
plot asymmetry: t = 3.2400, df = 4, p = 0.0317) (Figure 2B)
and R0 rate (Test for funnel plot asymmetry: t = 4.3507, df
= 4, p = 0.0122) (Figure 2C). There was no heterogeneity
differences with regards to resection rate, which ranged from
47 to 76% (random effect model 0.60 (95% CI 0.50–0.69) I2 =
54%, p = 0.06) (Figure 3A), R0 rate, which ranged from 81 to
95% (random effect model 0.86, 95% CI 0.79–0.91, I2 = 0%,
p= 0.64) (Figure 3B).
Depending on the different centers’ protocols, Gemcitabine
was used as single agent in 110 (40.6%) patients or in
combination with Docetaxel (67 patients, 24.7%) oxaliplatin (53
patients, 19.5%) S-I (25 patients, 9.2%) or other agents such
and Cisplatin, Capecitabine and 5FU. Median OS was 27.8
months (95%CI 23.9–31.6) in the patients who received NAT-
GEM followed by resection compared to 15.4 months (95%CI
12.3–18.4) for NAT-GEM without resection and 13.0 months
(95%CI 7.4–18.5) in the group of patients who received upfront
surgery from the study published by Jang et al. (Figure 4A) (7).
Patients receiving a multimodality treatment with NAT-GEM
followed by surgery had a significantly better OS compared
to both patients who did not complete the treatment with
surgery and the patients who had upfront surgery (p = 0.000)?.
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FIGURE 2 | (A). Funnel plot for survival outcomes. Test for funnel plot asymmetry: t = 1.4439, df = 4, p = 0.2223. (B). Funnel plot for resection outcomes. Test for
funnel plot asymmetry: t = 3.2400, df = 4, p = 0.0317. (C). Funnel plot for RO outcomes. Test for funnel plot asymmetry: t = 4.3507, df = 4, p = 0.0122.
Median OS for NAT-GEM +/– resection in the single studies
included in the IPD analysis was similar (p = 0.813): 26.9
months (95%CI 21.1–32.6) for Nagakawa et al. (16), 25.3 months
(95%CI 18.3–32.2) for Rose et al. (18), 21.2 months (95%CI
8.6–33.7) for Kim et al. (19), 22.2 (95%CI 16.5–27.8) for
Lee et al. (20), 17.5 months (95%CI 10.9–24.0) for Versteijne
et al. (17) and 22.9 months (18.8–26.7) for Jang et al. (7)
(Figure 4B).
Data on radiological response following NAT-GEM was
available for 200 patients, of which 76 (38%) achieved
downstaging. Median OS was significantly improved in
patients who achieved downstaging (28.7 months 95%CI
22.0–35.3 vs. 22.0 months; 95%CI 18.6–25.3; p = 0.026)
(Supplementary Figure 1).
Median disease-free survival (DFS) in the entire cohort
was 11.8 (95%CI 9.3–14.3). Data on toxicity was available
for 244 patients: 27 (11.2% did not experience toxicity from
GEM-NAT, 139 patients (56.9%) had toxicity grade I-II, whilst
toxicity III and IV was seen in 92 (37.7%) and 20 (8.2%) of
the patients.
Information on oncological complete resection was
available for 158 patients who underwent resection
following GEM-NAT. R0 resection was achieved in 130
patients (82.3%) with a median OS of 29.3 months (95%
CI 24.3–34.2) vs. 16.2 months (95% CI 7.9–24.5) in the R1
group (p= 0.001).
DISCUSSION
Different strategies combining surgery and chemoradiotherapy
are being investigated for BR- PDAC (21). Although neoadjuvant
therapy had shown beneficial effects in BR-PDAC by improving
overall survival and the rate of R0 resection, treatment
sequencing and specific elements of neoadjuvant treatment are
still under investigation (17, 22–24). The benefit of gemcitabine-
based combination therapies is hotly debated and reported
results have shown conflicting conclusions (25–27). A previous
meta-analysis of 20 phase III RCT (n = 6,296) has shown no
differences in overall survival between single agent gemcitabine
and combination gemcitabine therapy in inoperable pancreatic
cancer (RR 0.93, 95% CI 0.84–1.03, p = 0.17) (25). Therefore,
the evidence to recommend a specific neoadjuvant regimen is
limited and practices vary with regard to the use of combination
chemotherapy and/or radiotherapy (8–10). This meta-analysis of
different gemcitabine-based protocols has shown similar results
to other reported neoadjuvant regimens (5), with a pooled
median patient-level OS of 27.2 (95% CI 23.0–31.3) months in
resected patients.
Up front surgery for BR-PDAC is still considered an option
in some centers (28, 29). The number of RCTs comparing
neoadjuvant therapy in BR-PDAC vs. up front surgery are very
limited and the outcomes of different regimens still unknown
(9, 30). Recently, OS in a RCT was significantly better in the
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FIGURE 3 | Forest plots showing HR of survival (A), rates of Resection Rate (B) and RO (C).
gemcitabine-based neoadjuvant chemoradiation treatment than
in the upfront surgery group (21 vs. 12 months p = 0.028) and
the results has been confirmed by the present meta-analysis (7).
The Dutch Pancreatic Cancer Group reported in a randomized
multicenter phase III trial a better OS in the preoperative
gemcitabine arm than in the immediate surgery group (median
13.5 vs. 17.1 months; HR 0.71; p = 0.074) (17). In the present
meta-analysis, the group of patients that did not proceed to
surgery had similar median OS [20.4 (95% CI 12.7–28.0)] to the
upfront surgery group in these two RCTs. Therefore, we speculate
that this result confirms the findings and supports the use of
neoadjuvant therapy to select patients with a favorable biological
disease and to provide a palliative option in the non-responder or
unresected groups.
Studies have demonstrated that neoadjuvant treatment does
not decrease the rate of surgical resection in BR-PDAC and may
lower surgical complication rates (31–35). This is likely due to
a selection bias for healthier patients that are able to complete
neoadjuvant treatment. Chemotherapy combinations are likely
more efficacious in the neoadjuvant setting but are associated
with increased toxicities. In advanced disease, gemcitabine has
less Grade 3–4 toxicity as compared to FOLFIRINOX. As NAT, in
one phase II study, a significant number of patients (23%) did not
proceed to surgery due to toxicities or poor performance status
following neoadjuvant gemcitabine and oxaliplatin (34). The
present results seem to confirm that Gem-based chemotherapy
is better tolerated than multidrug regimens with a minimal
drop-out rate not related to progression disease.
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FIGURE 4 | Kaplan-Meier curves for pooled overall survival in patients receiving NAT-GEM following by resection and patients who received GEM-NAT but did not
undergo resection or underwent upfront surgery (A) and amongst Treatment Protocols (B).
Neoadjuvant therapy has permitted tumor down-staging
and resection with similar survival rates after surgery and
a decrease in the rate of margin-positive resections (36–
38). The resection rates of patients with BR-PDAC that
ultimately undergo pancreatectomy after neoadjuvant therapy
range from 47 to 76% with an associated 81 to 95%
R0 resections (7, 16–20, 39). In this meta-analysis, despite
the variability amongst the protocols, no difference was
observed within the IPD cohort in the R0 rates among
drug regimens with the majority of resected patients having
negative margins.
The strength of the present study is that all the data
were reappraised and reclassified as BR-PDAC at an IPD
level according to the radiological criteria. However, the
main limitation of the present study is the heterogeneity
of the included studies, although only one study is a
retrospective study. In particular, some studies failed to
report eligibility criteria for neo-adjuvant treatment expect
that for the BR-PDAC stage (18, 20). A second limitation
is related to the evaluation of the safety and tolerability of
neoadjuvant therapy. Characteristically, retrospective studies did
not include information about dose reduction or discontinuation
of study drugs due to adverse events. Finally, there was
paucity of data on adjuvant or second line chemotherapy.
Therefore, we were not able to assess their impact on the
survival outcomes.
In conclusion, to the best of our knowledge, the present
meta-analysis is the first evidence-based data aggregation of
gemcitabine-based Neoadjuvant Treatment in BR-PDAC. The
results support the use of GEM-NAT for BR-PDAC in routine
practice to select patients where surgery may contribute the
most benefit. Moreover, the general tolerability of GEM-
NAT may improve the rate of patients undergoing surgery
following NAT and receiving adjuvant treatment related to lower
post-operative complications and/or decline in the functional
status (40, 41).
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